Monell Center Study Identifies GLP-1 Therapies as a Possible Treatment for Rare Genetic Disorder Bardet-Biedl Syndrome
 | Newswise

Monell Center Study Identifies GLP-1 Therapies as a Possible Treatment for Rare Genetic Disorder Bardet-Biedl Syndrome | Newswise

Newswise — PHILADELPHIA, PA (April 17, 2025) – A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for individuals living with Bardet-Biedl Syndrome (BBS), a rare genetic disorder characterized by early-onset obesity, compulsive eating, and cognitive impairments. The Monell team and colleagues identified that GLP-1 receptor…

Read More
How Accurate Is BMI as a Health Indicator? | Newswise

How Accurate Is BMI as a Health Indicator? | Newswise

Newswise — MOULTRIE, GA — At most medical checkups, patients step on a scale to measure their current weight. Physicians then often use this number to calculate the patient’s body mass index (BMI), a commonly used indicator of overall health. This measurement is especially relevant when considering eligibility for GLP-1 weight loss drugs such as…

Read More
Under Embargo: Landmark Research Recommends Gastric Bypass for People with Severe Obesity Undergoing Surgery | Newswise

Under Embargo: Landmark Research Recommends Gastric Bypass for People with Severe Obesity Undergoing Surgery | Newswise

Embargoed until 23:30 UK time Monday, 31 March Newswise — Landmark research recommends gastric bypass for people with severe obesity undergoing surgery Gastric bypass is the most clinically and cost effective form of interventional surgery for people living with severe obesity, reveals landmark research funded and supported by the National Institute for Health and Care…

Read More
Under Embargo: Landmark Research Recommends Gastric Bypass for People with Severe Obesity Undergoing Surgery | Newswise

Improving GLP-1 Drug Delivery by ‘Painting’ It on Antibodies | Newswise

Newswise — SAN DIEGO, March 23, 2025 — Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss. Unfortunately, shortages and high costs have made it difficult for people to start and maintain treatment. Now, researchers report a drug delivery system that “paints” these peptides directly on the antibodies they…

Read More
Under Embargo: Landmark Research Recommends Gastric Bypass for People with Severe Obesity Undergoing Surgery | Newswise

Are GLP-1s the First True Longevity Drug? | Newswise

Newswise — With GLP-1 drugs dominating headlines for their impact on weight loss and metabolic health, new discussions around their potential role in extending healthy lifespan are emerging. Dr. Christoph Westphal, Co-founder and General Partner of Longwood Fund, and Dr. Jarod Rutledge, Biomarkers Lead at the Amaranth Foundation, highlight why GLP-1s could be the first…

Read More